Explained - Why Laurus Labs share price fell 10% on Monday

详细摘要
At the end of the September quarter, Satyanarayana Chava held 15.7 lakh shares of the company, of which he has sold 14.85 lakh shares in his individual capacity. His other holdings come from NSN Holdings, which he represents. NSN has a 22.97% stake in Laurus at the end of the September quarter. Total promoter holding in the company stood at 27.47%.
Shares of Laurus Labs Ltd. fell as much as 10% on Monday, November 16, marking its biggest single-day fall in nearly two years. The last instance of the stock falling by such a quantum was back in January 2025.
The stock fell after NSE disclosures showed that Promoter Satyanarayana Chava, along with other members designated as promoters or key personnel sold over 20 lakh shares of the company in the open market on November 11.
According to the Disclosures, Chava sold 14.85 lakh equity shares of the company, while LEVEN HOLDINGS, represented by VV Ravi Kumar, also designated as a Promoter, sold 4.78 lakh shares of the company.
Others mentioned in the disclosure, sold between 1,000 to 1 lakh shares.
The selling comes on the day the stock had touched a record high of ₹2,488 on the National Stock Exchange (NSE).
At the end of the September quarter, Satyanarayana Chava held 15.7 lakh shares of the company, of which he has sold 14.85 lakh shares in his individual capacity. His other holdings come from NSN Holdings, which he represents. NSN has a 22.97% stake in Laurus at the end of the September quarter. Total promoter holding in the company stood at 27.47%.
Mutual Funds held a 8.26% stake in Laurus at the end of the September quarter, while SBI Life Insurance had a 1.07% stake. Foreign Portfolio Investors (FPIs) had a 30.84% stake, while 3 lakh small retail shareholders, or those with an authorized share capital of up to ₹2 lakh, had a 12.15% stake in the company.
During the second quarter, Laurus Labs' growth was driven by the CDMO segment and fixed dose formulations, while margins were aided by higher CDMO revenue and operational leverage. CDMO revenue grew by 75% during the quarter, while FDF revenue grew by 31% from last year.
Shares of Laurus Labs are trading 9.1% lower on Monday at ₹2,202.2. The stock is still up nearly 100% so far in 2026.
文章开头,摘自CNBC-TV18。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.cnbctv18.com)



